ORITAVANCIN
Oritavancin is a longacting lipoglycopeptide antibiotic inhibiting cellwall synthesis in grampositive bacteria. Benefits include singledose therapy for skin infections. Side effects include headache, nausea, infusion reactions, and coagulation test interference. Only GMP materials will be supplied, logistics all according to GDP.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
ORITAVANCIN shows a complex, multipathway biochemical interaction profile involving modulation of enzymeregulated catalytic cycles, receptorlevel signalling networks, intracellular ion dynamics, mitochondrial respiratory control, redoxbalance adaptation, cytoskeletal organisation and transcriptionfactor regulatory behaviour. Its physicochemical structure supports direct or indirect interaction with catalytic residues, allosteric pockets, membranespanning receptors, signalling intermediates and structural proteins, enabling influence over secondmessenger pathways (Ca²⁺, cAMP, IP, DAG), phosphorylation kinetics, ROS generation and mitochondrial ATPsynthesis efficiency.
Depending on concentration, exposure duration and biological substrate, ORITAVANCIN may shift metabolic routing, alter vesicular transport, influence chromatin accessibility, modify transcriptional clusters, or recalibrate mitochondrial stressresponse thresholds across diverse experimental models.
Benefits and Advantages
Common applications in research environments include:
- Highresolution receptorligand interaction analysis and molecular docking validation
- Enzymekinetic dissection and catalyticpathway reconstruction
- Mitochondrialperformance assays, redoxstress modelling and ATPflux quantification
- Multiomics integration: transcriptomics, metabolomics, proteomics, phosphoproteomics
- Cytoskeletaldynamics studies involving actin, tubulin and membranetension regulation
- Apoptosis, autophagy, necroptosis, ferroptosis and stressresponse pathway mapping
- SAR (structureactivity relationship) investigation and molecularoptimisation workflows
- Preclinical pharmacodynamic modelling and mechanistic doseresponse assays
Side Effects and Risks
Potential laboratoryobserved risks include:
- ROS accumulation and oxidativestress imbalance
- Mitochondrial hyperactivation or respiratorychain suppression
- Disruption of Ca²⁺/Na⁺/K⁺ ionic homeostasis and ionchannel behaviour
- Unintended receptor crossactivation or inhibitory interference
- Cytoarchitectural destabilisation, membrane fragility or impaired trafficking
- Dosedependent cytotoxicity and activation of apoptosis/autophagy signalling
- Transcriptional and epigenetic instability under prolonged exposure
- Inflammatory pathway activation (NF-κB, MAPK, JNK)
Use exclusively under controlled laboratory conditions, following strict biosafety and handling protocols.
Only GMP materials will be supplied, logistics all according to GDP.
Datasheet
| Molecular Formula | C86H97Cl3N10O26 |
|---|---|
| Molecular Weight | 1793.1 g/mol |
| CAS Number | 171099-57-3 |
| Storage Condition | Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light. |
| Solubility | Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance. |
| Purity | Purity information is available upon request (COA). |
| Synonym | Oritavancin; 171099-57-3; LY333328; Chlorobiphenyl-chloroeremomycin; LY-333328 |
| IUPAC/Chemical Name | (1S,2R,18R,19R,22S,25R,28R,40S)-2-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5R,6S)-4-[[4-(4-chlorophenyl)phenyl]methylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-18,32,35,37-tetrahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid |
| InChl Key | VHFGEBVPHAGQPI-LXKZPTCJSA-N |
| InChl Code | InChI=1S/C86H97Cl3N10O26/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-/m0/s1 |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
